On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed ...
Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer treatment, but data from a forthcoming study could quickly shake up the ...
In 2023, TAGRISSO plus savolitinib received Fast Track designation from the Food and Drug Administration (FDA) in this setting. TAGRISSO plus datopotamab deruxtecan-dlnk showed encouraging response ...
Longer-term follow up in the FLAURA2 Phase III trial confirms the favorable benefit-risk profile of this combination Overall survival results reinforce TAGRISSO as the backbone therapy in EGFRm lung ...
J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...
INDIANAPOLIS (WISH) — A new targeted therapy called Osimertinib is significantly improving outcomes for patients with a specific type of lung cancer, according to a study released in 2024. The drug, ...
Hosted on MSN
AstraZeneca rises as cancer drugs power Q4 beat
AstraZeneca (AZN) shares added ~2% in the premarket on Tuesday after the Anglo-Swedish drugmaker exceeded Street forecasts with its Q4 2025 financials, thanks mainly to its oncology portfolio. The U.K ...
AstraZeneca AZN stock has risen 15% so far this year compared with an increase of 0.2% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.
Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) with the addition of pemetrexed and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results